Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease

[1] Arora M(2016)Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transpl 22 449-55

[2] Cutler CS(2018)Success of immunosuppressive treatments in patients with chronic graft-versus-host disease Biol Blood Marrow Transpl 24 555-62

[3] Jagasia MH(2021)Steroid-refractory chronic graft-versus-host disease: treatment options and patient management Bone Marrow Transpl 56 2079-87

[4] Pidala J(2021)Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease N. Engl J Med 385 228-38

[5] Chai X(2021)Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study Blood 138 2278-89

[6] Martin PJ(2012)IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD Blood 120 4093-103

[7] Lee SJ(2014)Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease Blood 123 3832-42

[8] Nguyen TD(2015)Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease Blood 125 4085-94

[9] Onstad L(2015)The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis Pharm Rev 67 103-17

[10] Bar M(2022)Three US Food and Drug Administration-approved therapies for chronic GVHD Blood 139 1642-5

[1] Arora M(2016)Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transpl 22 449-55

[2] Cutler CS(2018)Success of immunosuppressive treatments in patients with chronic graft-versus-host disease Biol Blood Marrow Transpl 24 555-62

[3] Jagasia MH(2021)Steroid-refractory chronic graft-versus-host disease: treatment options and patient management Bone Marrow Transpl 56 2079-87

[4] Pidala J(2021)Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease N. Engl J Med 385 228-38

[5] Chai X(2021)Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study Blood 138 2278-89

[6] Martin PJ(2012)IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD Blood 120 4093-103

[7] Lee SJ(2014)Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease Blood 123 3832-42

[8] Nguyen TD(2015)Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease Blood 125 4085-94

[9] Onstad L(2015)The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis Pharm Rev 67 103-17

[10] Bar M(2022)Three US Food and Drug Administration-approved therapies for chronic GVHD Blood 139 1642-5